TRCT
GTBP icon

Tower Research Capital (TRC)’s GT Biopharma GTBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$831 Hold
68
– – ﹤0.01% 4937
2026
Q1 		$693 Hold
68
– – ﹤0.01% 4798
2025
Q4 		$1.34K Hold
68
– – ﹤0.01% 4711
2025
Q3 		$999 Buy
68
+50
+278% +$1.87K ﹤0.01% 4895
2025
Q2 		$1.61K Sell
18
-19
-51% -$1.23K ﹤0.01% 4775
2025
Q1 		$1.97K Sell
37
-80
-68% -$4.71K ﹤0.01% 4613
2024
Q4 		$8.9K Buy
117
+51
+77% +$3.45K ﹤0.01% 3957
2024
Q3 		$3.79K Sell
66
-21
-24% -$1.25K ﹤0.01% 4773
2024
Q2 		$6.15K Sell
87
-5
-5% -$447 ﹤0.01% 4614
2024
Q1 		$10.2K Buy
92
+66
+254% +$8.72K ﹤0.01% 3732
2023
Q4 		$5.04K Sell
26
-1
-4% -$183 ﹤0.01% 4889
2023
Q3 		$4.86K Buy
27
+1
+4% +$207 ﹤0.01% 4805
2023
Q2 		$6.18K Sell
26
-12
-32% -$3.11K ﹤0.01% 4728
2023
Q1 		$16K Buy
38
+17
+81% +$9.74K ﹤0.01% 3696
2022
Q4 		$14K Buy
21
+14
+200% +$17.5K ﹤0.01% 3507
2022
Q3 		$9K Buy
7
+2
+40% +$3.82K ﹤0.01% 4654
2022
Q2 		$11K Buy
5
+1
+25% +$1.9K ﹤0.01% 4373
2022
Q1 		$9K Sell
4
-1
-20% -$2.21K ﹤0.01% 4453
2021
Q4 		$12K Hold
5
– – ﹤0.01% 4281
2021
Q3 		$23K Buy
+5
New +$37.6K ﹤0.01% 3592
2021
Q2 		– Sell
-2
Closed -$20.8K – 4813
2021
Q1 		$9K Buy
+2
New +$8.74K ﹤0.01% 4422

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Tower Research Capital (TRC)'s GTBP Position: Q2 2026 in Review

Tower Research Capital (TRC) held its GT Biopharma (GTBP) position steady in Q2 2026 at 68 shares worth $831. The position accounts for ﹤0.01% of the portfolio, ranked #4937.

Tower Research Capital (TRC) first reported a position in GTBP in Q1 2021 and has held it in 21 quarters since. The position peaked at $23K in Q3 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Tower Research Capital (TRC) held 68 shares of GT Biopharma worth $831 as of Q2 2026.
  • Tower Research Capital (TRC) left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4937 holding.
  • Tower Research Capital (TRC) first reported a position in GT Biopharma in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s GT Biopharma position peaked at $23K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.